Molecular Partners (MOLN) Stock: Buy, Sell, or Hold?
MOLN - Molecular Partners AG American Depositary Shares
$3.67
0.06 (1.68%)
▲
5d:
+3.09%
30d:
-12.62%
90d:
-7.32%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 29, 2026
2d
Get Alerted When MOLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MOLN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: MOLN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: MOLN is currently trading at $3.67, which is considered slightly low relative to its 30-day fair value range of $3.64 to $4.05. From a valuation perspective, the stock is trading at a discount (Forward PE: -27.0) compared to its historical average (31.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MOLN is showing sideways momentum. Immediate support is located at $3.52, while resistance sits at $3.88.
Market Sentiment: MOLN scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.50 (+186.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MOLN is showing sideways momentum. Immediate support is located at $3.52, while resistance sits at $3.88.
Market Sentiment: MOLN scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.50 (+186.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.64 -
$4.05
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (76/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 186.0% below Wall St target ($10.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 76/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$3.64 -
$4.05
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.52
Resistance Level
$3.88
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.99
Wall Street Target
$10.50
(+186.0%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-27.0 vs 31.9
CHEAP
Share & Embed Analysis
Last updated: October 25, 2026 10:37 PM ET
Data refreshes hourly during market hours. Next update: 11:37 PM
Data refreshes hourly during market hours. Next update: 11:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MOLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$280 | 43 HOLD |
